Furthermore, we suggest that DANGER and DAPK could be attractive pharmaceutical targets for overcoming HG-induced radioresistance of NSCLC and ultimately contribute to the effective treatment of lung cancer with radiation. Here, ITPRIP is linked to non-small cell lung carcinoma.